Last reviewed · How we verify
Dermoval
Dermoval is a Small molecule drug developed by University Hospital, Rouen. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dermoval |
|---|---|
| Sponsor | University Hospital, Rouen |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid (PHASE4)
- Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid (PHASE4)
- Dupilumab Impact on Skin Resident Memory T Cells (NA)
- Vasoconstriction Trial With LEO 90100 Aerosol Foam (PHASE1)
- Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dermoval CI brief — competitive landscape report
- Dermoval updates RSS · CI watch RSS
- University Hospital, Rouen portfolio CI
Frequently asked questions about Dermoval
What is Dermoval?
Who makes Dermoval?
What development phase is Dermoval in?
Related
- Manufacturer: University Hospital, Rouen — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing